16 Hour MAT Waiver Course for PAs

Target Audience: 

This activity will assist physician assistants (PAs) who wish to apply for a waiver to prescribe buprenorphine for the treatment of opioid use disorders.  

In accordance with the Comprehensive Addiction and Recovery Act (CARA), PAs must complete 24 hours of specialized training to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. This activity will allow PAs to fulfill the 16 hour portion of the 24 hour MAT waiver training requirement.

Educational Objectives:

At the conclusion of this activity, learners should be able to:

  • Provide information about the pharmacology and clinical use of buprenorphine
  • Provide information on other approved antagonist and agonist medications to treat opioid use disorder
  • Provide resources needed to set up office-based treatment of opioid use disorder using buprenorphine  

Fee: No cost 

image

Joint Accreditation Statement:  In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC) and the American Academy of PAs (AAPA) to provide continuing education for the healthcare team.
image

AAPA Credit Designation Statement Enduring Material: American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 16 AAPA Category 1 CME credits. Approval is valid until 2/16/2020. PAs should only claim credit commensurate with the extent of their participation. 

Method of participation in the activity: To be awarded a maximum of AAPA Category 1 CME credits and a Certificate of Completion you must:

  • Review 16 training modules (16 hours) provided in this activity.
  • Earn a passing score of 75% on each of the module’s post-tests.
  • Complete a final evaluation and follow instructions at the end of the course regarding how to retrieve your Certificate of Completion as well as your continuing credit certificate*.

*Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.

Disclosures: AAAP's CME program aims to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, disclosure information from all series planners and speakers is provided during the planning process to ensure resolution of any identified conflicts. The following PCSS-MAT AAAP staff and CPD Committee members have reported that they have no commercial relationships relevant to the content of this activity to disclose: Dean Krahn, MD, Michael Goedde, MD, Thomas Penders, MD, Alan Gordon, MD, Oliveria Bugunovic, MD, Margi Kotz, MD, Kathryn Cates-Wessel, Justina Andonian and Miriam Giles. Kevin Sevarino, MD owns a small amount of stock in GSK. Content Developers for this 16 hour course disclose the following: https://30qkon2g8eif8wrj03zeh0...

Disclosure of Unlabeled Medication Use:Faculty have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. AAAP has determined that all scientific research referred to, reported, or used in this course conforms to the generally accepted standards of experimental design, data collection, and analysis.  

Support for the Program:

Funding for this initiative was made possible (in part) by grant no. 5U79TI026556 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


Key:

Complete
Failed
Available
Locked
Consent to Release Information
1 Question
1 Question Permission to Release Information Regarding Completion of Course to Center for Substance Abuse Treatment (CSAT)
Module 1: Administrative, Medico-Legal, and Regulatory Aspects of Opioid Use Disorder Medication-Assisted Treatment
Open to download resource.
Open to download resource. Educational Objectives for Module 1 At the conclusion of this activity participants should be able to: -Describe the regulatory oversight for opioid agonist replacement treatment -State the guidelines for documentation and informed consent procedures when providing opioid use disorder (OUD) medication-assisted treatment (MAT) -Identify how to determine the adequate level of psychosocial treatment and frequency of pharmacotherapy visits when providing MAT -Implement documentation and administrative practices into care of patients receiving OUD MAT
Module 1 Post-test
# of Questions: 5 | Total Points: 5 | Passing Score:  4
# of Questions: 5 | Total Points: 5 | Passing Score:  4
Module 2: Drug Diversion: How to Avoid Becoming an Unwitting Participant
Open to download resource.
Open to download resource. Educational Objectives for Module 2: At the conclusion of this activity participants should be able to: -Define the scope of the problem of healthcare facility drug diversion in the United States. -Describe methods of diversion and how transaction analytics can be used for identification. -Describe measures providers can take to protect themselves from being implicated in diversion schemes.
Module 2 Post-Test
# of Questions: 4 | Total Points: 4 | Passing Score:  3
# of Questions: 4 | Total Points: 4 | Passing Score:  3
Module 3: MAT of OUD - Progress and Challenges
Open to download resource.
Open to download resource. Educational Objectives for Module 3 At the conclusion of this activity participants should be able to: -Discuss the impact that prescription drug misuse has on the healthcare system -Discuss development in research and treatment
Module 3 Post-Test
# of Questions: 3 | Total Points: 3 | Passing Score:  3
# of Questions: 3 | Total Points: 3 | Passing Score:  3
Module 4: Motivational Interviewing
Open to download resource.
Open to download resource. Educational Objectives for Module 4: At the conclusion of this activity participants should be able to: -Describe four fundamental principles of Motivational Interviewing. -Use specific Motivational Interviewing approaches to help patients move through the stages of change. -Integrate Motivational Interviewing psychotherapy with other psychosocial and psychopharmacological interventions.
Module 4 Post-Test
# of Questions: 5 | Total Points: 5 | Passing Score:  4
# of Questions: 5 | Total Points: 5 | Passing Score:  4
Module 5: Developing a Behavioral Treatment Protocol in Conjunction with MAT
Open to download resource.
Open to download resource. Educational Objectives for Module 5: At the conclusion of this activity participants should be able to: Identify the importance of evidenced based practices for substance use disorders. Identify four key components of a behavioral treatment protocol. Provide examples for each of the four components. Describe the basic tenets of the Community Reinforcement and Family Training approach.
Module 5 Post-Test
# of Questions: 9 | Total Points: 9 | Passing Score:  7
# of Questions: 9 | Total Points: 9 | Passing Score:  7
Module 6: SBIRT for Substance Use Disorders in Primary Care
Open to download resource.
Open to download resource. Educational Objectives for Module 6: At the conclusion of this activity participants should be able to: -Identify appropriate screening tools to detect substance use disorders -Determine the severity of substance use disorders to help guide treatment -Describe the components of a brief intervention Provide follow-up appointments and referrals as needed
Module 6 Post-Test
# of Questions: 5 | Total Points: 5 | Passing Score:  4
# of Questions: 5 | Total Points: 5 | Passing Score:  4
Module 7: Opioid Dependence in Pregnancy - Clinical Challenges
Open to download resource.
Open to download resource. Educational Objectives for Module 7: At the conclusion of this activity participants should be able to: -Discuss the epidemiology of substance use disorders (opioid use disorders in particular) in pregnant women -Describe both the maternal and fetal/infant risks of opioid use disorders in pregnancy -Discuss the range of screening approaches to opioid use disorders in pregnancy -State mandatory reporting issues -List the various medication-assisted-treatment (MAT) options for opioid dependent pregnant women including: Naltrexone, Methadone, and buprenorphine -Discuss behavioral treatment options for management of opioid use disorders in pregnant women
Module 7 Post-Test
# of Questions: 5 | Total Points: 5 | Passing Score:  4
# of Questions: 5 | Total Points: 5 | Passing Score:  4
Module 8: Preventing Opioid Overdose with Education and Naloxone Rescue Kits
Open to download resource.
Open to download resource. Educational Objectives for Module 8: At the conclusion of this activity participants should be able to: -Explain the epidemiology of overdose -Explain the rationale for and scope of overdose education and naloxone distribution (OEND) programs -Incorporate OEND into medication-assisted treatment settings -Educate patients about overdose risk reduction -Prescribe naloxone rescue kits
Module 8 Post-Test
# of Questions: 5 | Total Points: 5 | Passing Score:  4
# of Questions: 5 | Total Points: 5 | Passing Score:  4
Module 9: A Primer on Antagonist-Based Treatment of OUD
Open to download resource.
Open to download resource. Educational Objectives for Module 9: At the conclusion of this activity participants should be able to: -Describe the evolution of antagonist-based treatment for opioid dependence -State guidelines to select most appropriate patients for treatment with naltrexone -Determine pharmacological strategies to initiate treatment with naltrexone -Identify clinical challenges encountered during treatment with naltrexone -Implement naltrexone in addiction practice competently
Module 9 Post-Test
# of Questions: 5 | Total Points: 5 | Passing Score:  4
# of Questions: 5 | Total Points: 5 | Passing Score:  4
Module 10: Patient-Centered Urine Drug Testing - Facts You Should Know
Open to download resource.
Open to download resource. Educational Objectives for Module 10: At the conclusion of this activity participants should be able to: -Discuss testing methodology in urine drug testing (UDT) -Differentiate between qualitative vs. quantitative UDT -Review drug metabolism -Explain sample integrity check (SIC) -Recommend “best clinical practices” with the use of UDT
Module 10 Post-Test
# of Questions: 5 | Total Points: 5 | Passing Score:  4
# of Questions: 5 | Total Points: 5 | Passing Score:  4
Module 11: Psychiatric Comorbidities
Open to download resource.
Open to download resource. Educational Objectives for Module 11: At the conclusion of this activity participants should be able to: -Recognize that psychiatric illnesses and substance use disorders commonly co-occur -Determine how to screen for and identify comorbid psychiatric diagnoses -Distinguish the distinction between independent psychiatric illness and substance-induced disorders -Develop treatment plans when comorbidities are identified
Module 11 Post-Test
# of Questions: 5 | Total Points: 5 | Passing Score:  4
# of Questions: 5 | Total Points: 5 | Passing Score:  4
Module 12: Managing Acute & Chronic Pain with Opioid Analgesics in Patients on Medication Assisted Treatment (MAT)
Open to download resource.
Open to download resource. Educational Objectives for Module 12: At the conclusion of this activity participants should be able to: -Describe the epidemiology of pain among individuals with opioid use disorder and factors that influence the overlap -Contrast the key role of patient and provider perspectives on pain management -Discuss general principles of and different specific approaches for acute and chronic pain management in patients with opioid use disorder treated with methadone, buprenorphine, or naltrexone
Module 12 Post-Test
# of Questions: 5 | Total Points: 5 | Passing Score:  4
# of Questions: 5 | Total Points: 5 | Passing Score:  4
Module 13: Co-occurring Psychiatric Illness and Substance Use in Youth
Open to download resource.
Open to download resource. Educational Objectives for Module 13: At the conclusion of this activity participants should be able to: -Identify the most common psychiatric problems by quickly screening for mental health symptoms in youth -Utilize screening tools when prescribing opioids for youth -Combine both mental health and substance use screening into routine pediatric settings
Module 13 Post-Test
# of Questions: 6 | Total Points: 6 | Passing Score:  5
# of Questions: 6 | Total Points: 6 | Passing Score:  5
Module 14: Counseling & MAT: Better Outcomes with Integrated Care
Open to download resource.
Open to download resource. Educational Objectives for Module 14: At the conclusion of this activity participants should be able to: -Identify 4 Evidence Based Practices (EBPs) for use to enhance MAT outcomes -Cognitive Behavioral Therapy (CBT) -Acceptance & Commitment Therapy -Motivational Interviewing -Twelve-Step Facilitation -Identify skills from each of the above EPBs that may be used in a variety of treatment settings -Increase understanding of SUD mutual self-help groups
Module 14 Post-Test
# of Questions: 5 | Total Points: 5 | Passing Score:  4
# of Questions: 5 | Total Points: 5 | Passing Score:  4
Module 15: MAT in the OTP Setting: Integrating the Three Approved Medications (Methadone, Buprenorphine, ER Naltrexone)
Open to download resource.
Open to download resource. Educational Objectives for Module 15: At the conclusion of this activity participants should be able to: -Discuss the unique characteristics of Opioid Treatment Programs (OTPs) -Identify OTPs as part of the continuum of care -Assess the infrastructure available to support medication management in OTPs -Review challenges and opportunities in integrating all three medications (methadone, buprenorphine and extended release naloxone) into the OTP setting -Discuss the clinical and operational issues related to medication choice in the OTP setting.
Module 15 Post-Test
# of Questions: 5 | Total Points: 5 | Passing Score:  4
# of Questions: 5 | Total Points: 5 | Passing Score:  4
Module 16: Current Understanding of the Interaction of Benzodiazepines and Buprenorphine
Open to download resource.
Open to download resource. Educational Objectives for Module 16: At the conclusion of this activity participants should be able to: -Describe the basic pharmacology of benzodiazepines. -Determine the effects of opiates on respiratory function. -Describe the hazards of combining benzodiazepines and buprenorphine. -List alternatives to the treatment of anxiety in the opiate dependent patient.
Module 16 Post-Test
# of Questions: 6 | Total Points: 6 | Passing Score:  5
# of Questions: 6 | Total Points: 6 | Passing Score:  5
Satisfaction Survey
Please answer the following evaluation questions to end this course and obtain your Certificate of Completion. Note: upon completion of this evaluation, you will receive your certificate of completion via email. Please be sure to check your spam folder for this certificate.